Solian is indicated for the treatment of acute and chronic schizophrenic disorders, in which positive symptoms (such as delusions, hallucinations, thought disorders) and/or negative symptoms (such as blunted affect, emotional and social withdrawal) are prominent, including patients characterised by predominant negative symptoms.
Aerie Pharmaceuticals announced the submission of its New Drug Application (NDA) to the FDA for Rhopressa (netarsudil ophthalmic solution) 0.02%....
As a topical ocular irrigating solution.
Treatment of symptomatic anaemia associated with chronic renal failure (CRF) in adults and paediatric patients (see section 4.2). Treatment of symptomatic anaemia in adult cancer patients with non-myeloid malignancies receiving chemotherapy.
Aclaris Therapeutics, Inc. announced positive results from its Phase III clinical trial, THWART-2 (WART-302), of A-101 45% Topical Solution (A-101...
Eton Pharmaceuticals, Inc and Azurity Pharmaceuticals, Inc. announced that the FDA has approved Eprontia (topiramate) oral solution, 25mg/mL.